URGN
BUYNeutralComposite
70.90
Technical
96.20
Fundamental
54.00
Rank
—
Price
46.43
Hurst
0.46
As of
Aug 6, 2026
Daily
UroGen Pharma Ltd.
HealthcareBiotechnologyUroGen Pharma Ltd. is a biotechnology company focused on developing treatments for bladder and upper urinary tract cancers. The company offers Zusduri and Jelmyto, approved medications for non-muscle invasive bladder cancer, along with several drug candidates in clinical trials that use its proprietary hydrogel delivery technology to administer chemotherapy directly to affected tissues. UroGen has partnerships with other pharmaceutical companies to expand its pipeline of urological cancer therapies.
Market cap
$2.1B
P/E (trailing)
—
P/E (forward)
15.73
PEG ratio
—
Dividend yield
—
Beta
1.58
52w range
15.86 – 50.81
Return on equity
—
Profit margin
-51.73%
Revenue growth
+199.20%
Earnings growth
—
Price history
1Y: 43.95 (+132.9%) · range 16.42–50.29
Cycle position
50/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 23 · NOT READY · exit proximity 15
Conviction
27/ 100 · maturity 100%
VScore.4014
Buildup.2040
EMA entry setup.2523
Fundamentals.1554
Volume profile
POC
29.88
Price vs POC
+47.1%
Overhead supply
21%
Runway
+3.9%
Value area 16.50–41.89 · 21% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 0.182 | Sep 17, 2026 |
| earnings-surprise | 0.033 | Sep 3, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.58% | +10.29% | mature |
| 40d | -7.21% | +10.29% | 25/40d |